Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial


The latest publication by the Video Journal of Biomedicine summarizes the ARAMIS (Androgen Receptor Antagonizing Agent for Metastasis-free Survival) trial, which was published in the New England Journal of Medicine in September 2020. The trial was in adult participants with nonmetastatic, castration-resistant prostate cancer who received a trial treatment called darolutamide (brand name Nubeqa®). The summary also includes insights and perspectives from a participant who was in the ARAMIS trial and from a prostate cancer patient advocate. Original publication: Fizazi K, Blue I & Nowak JT. Darolutamide and survival in nonmetastatic, castration-resistant prostate cancer: a patient perspective of the ARAMIS trial....

To view this content, please register now for access

It's completely free